Replies to post #245791 on Biotech Values

[swampboots]

I have to admit that I sense there has been a gold mine in shorting small bio tech companies, but I am not greedy enough to reverse my temperamental rooting for the opposite.

[oc631]

The idea mRNA vaccines developed during the pandemic somehow greased the approval process for the gene therapy field is misguided. However there is an angle here for mRNA developers. Moderna is considering a strategy of advancing vaccines for Mpox, H5N1, and novel coronavirus variants of concern through P1 testing. If there are early indications of efficacy and safety further development will be halted and the vaccines will be categorized into a library which the FDA/CDC can select from and perhaps distribute under EUA if needed.

This is a new twist on a drug development strategy and a "platform approval approach".

[DewDiligence]

Have you gotten any feedback from people in the biotech industry on the ideas for gene-therapy programs that you posted? TIA